Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print   

Friday 23 July, 2021

Accrol Group Hldgs

Director Share Purchase

RNS Number : 3381G
Accrol Group Holdings PLC
23 July 2021
 

 

23 July 2021

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Accrol Group Holdings plc

("Accrol" or the "Company")

 

Director Share Purchase

 

Accrol (AIM:ACRL), the UK's leading independent tissue convertor, announces that Dan Wright, Executive Chairman of Accrol, has today purchased 232,558 ordinary shares of £0.001 each ("Ordinary Shares") at a price of £0.43 per Ordinary Share.

Following this purchase, he now holds 11,515,5431 Ordinary Shares representing 3.61% of the current Issued Share Capital of the Company.

1

8,476,713 of these shares are registered in the name of Gomrath Limited, a family investment company controlled by Dan Wright

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 


1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dan Wright

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001 each

 

 

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£0.43

232,558

d)

Aggregated information

- Aggregated volume

- Price


N /A - Single transaction

e)

Date of the transaction

23 J uly 2021

f)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

Richard Newman, Chief Financial Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas




Belvedere Communications Limited

 

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

Llew Angus

Tel:  +44 (0) 7407 023 147


[email protected]

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisitions of LTC in Leicester and JD in Flint, North Wales, the Group now operates from six manufacturing sites, including four in Lancashire, which generate revenues totalling c.16% of the £2.1bn UK retail tissue market.

 

For more information, please visit www.accrol.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUOOORAAUBUAR

a d v e r t i s e m e n t